AMD, Costco and AstraZeneca headline today's stock reports, with AI demand, membership growth and drug pipelines shaping their outlooks.
Zacks
More News
Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
AZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbacks
AstraZeneca's pipeline setbacks weigh on the stock, but blockbuster drugs, oncology growth and a strong launch pipeline offer reasons to stay invested.
Zacks
AZN's Tagrisso Plus Orpathys Study in First-Line NSCLC Meets Goal
AstraZeneca reports positive SANOVO data, showing Tagrisso plus Orpathys improved PFS in first-line EGFR-mutated NSCLC.
Zacks
AstraZeneca Shares Dual Oncology Clinical and Regulatory Victories
AstraZeneca announced positive Phase 3 lung cancer trial results and earned EU approval for its Enhertu breast cancer combination.read more...
Benzinga
From Padcev to PF-08634404: Pfizer's Oncology Growth Push
PFE's oncology growth is led by Padcev, while a broad pipeline and label expansions aim to fuel longer-term gains.
Zacks
SLS Stock Rises Overnight: Healthcare Execs Tout AML Drug As ‘Game Changer’ Ahead Of Final Trial Trigger
An AstraZeneca sales executive called the Phase 3 Regal trial a “game changer” for AML patients in their first or second complete remission.
Stocktwits
IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY
Ionis and AstraZeneca already disclosed on July 9 that the late-stage CARDIO-TTRansform missed its primary goal. Full data from the trial was unveiled on Friday.
Stocktwits
SNY Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell?
Sanofi's stock trades above key moving averages as Dupixent and new drugs drive growth, while pipeline setbacks and vaccine weakness weigh.
Zacks
SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study
Summit gains as positive HARMONi-GI1 data show ivonescimab's OS benefit in biliary tract cancer, expanding its potential beyond NSCLC.